A polipoprotein B (apoB), the structural protein of very lowdensity lipoproteins and chylomicrons, transports lipids from the liver and intestine to other tissues. Microsomal triglyceride transfer protein (MTP) interacts with apoB, 1-3 which may help apoB translocate and fold properly. 4 MTP also transfers lipids to apoB, prevents degradation, and promotes lipoprotein assembly. 5-8 MTP may also aid in the formation of lumenal lipid droplets that fuse with primordial lipoproteins during maturation. 9,10
and lipid synthesis, it may be useful as a potential therapeutic agent. 17 Furthermore, expression of Drosophila MTP with only phospholipid transfer activity (lacks triglyceride transfer activity) in liver-specific MTP knockout mice lowers plasma lipids and avoids steatosis. 18 Hence, agents that decrease triglyceride transfer without affecting phospholipid transfer may be of therapeutic significance. Bioinformatics can aid in identifying novel inhibitors. However, these efforts are hampered because of the lack of sufficient information about the structure-function of MTP. Comprehensive information about its structure-function and identification of mutations that alter MTP function may be valuable in developing inhibitors that partially inhibit MTP function and avoid side effects.
Abetalipoproteinemia (OMIM: number, 200100), a homozygous monogenic disorder, is caused by mutations in the MTTP gene 19, 20 that render the protein incapable of supporting apoB secretion. Patients have very low plasma lipids, no apoB-containing lipoproteins, lipid malabsorption, hepatic and intestinal steatosis, elevated plasma transaminases, fat-soluble vitamin deficiency, and neuropathy. Low-fat diets supplemented with medium-chain triglycerides and fat-soluble vitamins relieve the gastroenterological and neurological symptoms.
MTP is a heterodimer composed of the M subunit and protein disulfide isomerase (PDI). 21, 22 PDI helps maintain MTP solubility, retention in the endoplasmic reticulum (ER), and lipid transfer activity. [22] [23] [24] In the absence of a crystallographic structure, homology modeling with lipovitellin, an ancient lipid transfer protein, has provided a predictive model for the M subunit 5,6,23,25 with 3 major structural domains 6 : the N-terminal domain with 12 β-strands forming a β-barrel, the central α-helical domain with 17 α-helices, and the C-terminal domain with 2 β-sheets forming a hydrophobic pocket. Biochemical studies suggest that these different structural domains may carry out independent functions. 6 The N-terminal domain shares homology and interacts with the N-terminal β-barrel of apoB. 23, 26 It may also contain a phospholipid transfer site. 6 The middle α-helical domain interacts with PDI and is essential for lipid transfer activity. 23, 24 The C-terminal domain is responsible for bulk lipid transfer. 27, 28 Identification of small molecular weight inhibitors that inhibit either apoB-MTP (protein-protein) interactions 29 or lipid transfer activity 6, 29 has provided evidence for the presence of independent functional domains.
Evidence for the functional importance of different MTP domains has also been garnered by studying different abetalipoproteinemia mutations. Mutations in different domains do not associate with the severity of symptoms (steatosis, neurological defects, or gastrointestinal effects). However, abetalipoproteinemia mutations support the conclusions about the functional necessity of the middle α-helical and C-terminal domains. 30 Characterization of R540H highlighted the importance of the central α-helical region in lipid transfer activity 23 and PDI binding. 30 A second mutation, R540C, also abolished triglyceride transfer activity and decreased its solubility. 25 Similarly, a C-terminally truncated mutant lacking the last 20 amino acids does not bind PDI and is deficient in lipid transfer activity. 27 These studies indicated that PDI binding and lipid transfer activity might be interdependent. Indeed, loss of PDI binding is always associated with defects in lipid transfer activity; however, all missense mutations defective in lipid transfer activity do not reduce PDI binding. For example, mutations in the central α-helical (Y528H, L435H, and S590I) and C-terminal (G746E and N780Y) regions that abolish lipid transfer activity bind normally to PDI. 25, 30, 31 Three missense mutations in the N-terminal region have been identified in patients with abetalipoproteinemia (R46G, G264R, and H297Q); however, they seem to be silent mutations or polymorphisms. 25, 32, 33 G264R and H297Q were reported in 2 different compound heterozygotes; however, mutagenesis of these amino acids did not affect function. 24, 25, 28 Functional effects of R46G have not been investigated. Because it is found with a frequency of 1% in the 1000 genomes browser 34 and there is another polymorphism, R46W, at this residue, the abetalipoproteinemia phenotype in this subject may not be related to the R46G mutation. Although, I128T reduces the structural stability of the N-terminal domain, it does not reduce plasma lipids below the normal range. 35 Thus, these limited mutation studies suggest that the N-terminal domain may not be critical to MTP function.
Here, we report a novel deleterious missense mutation in the N-terminal domain that abolishes the ability of MTP to support apoB secretion. Biochemical and molecular characterizations have uncovered the presence of an internal salt bridge that is important for PDI binding and lipid transfer.
Methods
This study was approved by the ethics committees of participating institutions in accordance with ethical standards of the Helsinki Declaration. Informed consent was obtained from parents. Lipids were measured in plasma collected after an overnight fast. 36
Site-Directed Mutagenesis of MTTP cDNA
Via site-directed mutagenesis using specific primers ( Table I in 
Cell Culture and ApoB Secretion
Cos-7 cells were sequentially transfected with plasmids expressing human apoB48 (pCMV-hapoB48) 38 followed by plasmids expressing MTP 30, 37, 39 or mutants using Fugene HD (1 μg of cDNA: 4 μL of Fugene). After 32 hours, cells were incubated overnight with 1 mL of DMEM containing 10% fetal bovine serum. ApoB was measured in cells and media by ELISA. 38
Immunoflourescence
Cos-7 cells were transfected on cover slips with plasmids expressing wild-type (WT) or mutant MTP. After 48 hours, cells were fixed, blocked, and probed for FLAG and either calnexin or PDI as described in the Data Supplement. 30
Western Blotting
Cell homogenates (35 μg) were separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to membranes for Western blot analysis (Data Supplement). Blots were probed for proteins of interest and visualized in a phosphorimager.
MTP Purification
Lysates were incubated for 30 minutes and then centrifuged at 12 000g for 10 minutes at 4°C. The supernatant was rotated with either 40 μL of M2 agarose beads (Sigma, number A2220) or 1 μL of anti-FLAG antibody and 40 µL of A/G agarose beads for 3 hours at 4°C. FLAG-tagged proteins were eluted with 200 ng/μL of FLAG peptide (1 hour at 4°C).
Lipid Transfer Assays
Cell lysates (35 µg) were prepared using buffer K as described in the Data Supplement, and triglyceride transfer activity was determined. 40, 41 For phospholipid transfer, WT or mutant MTP was purified using M2 agarose beads. 37
PDI and ApoB17 Binding
For PDI binding, MTP or mutants were purified from Cos-7 cells lysed with Triton lysis buffer (Tris, 50 mmol/L; EDTA, 1 mmol/L; NaCl, 150 mmol/L; and Triton, 1%). Western blot was performed on purified MTP or mutants for PDI followed by MTP. For apoB binding, apoB or MTP was immunoprecipitated from cell lysates as described in the Data Supplement. Western blot was performed on the immunoprecipitates for both apoB and MTP.
Solubility
Cells expressing WT or mutant MTP were scraped in Triton lysis buffer and incubated on ice for 60 minutes. Lysates were centrifuged at 12 000g. Supernatants were centrifuged at 100 000g for 60 minutes at 4°C. The supernatants were collected, and the pellets were resuspended in Triton lysis buffer. Both fractions were run on 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel, transferred to nitrocellulose, and probed for FLAG.
Statistical Analyses
In Figures to determine significant differences among groups. The Mann-Whitney U test was then used to determine whether each mutant was significantly different from WT MTP. Significance (P≤0.05) is indicated by asterisks.
Results

Proband
The proband, a 4-month-old male child, was admitted to the Ankara Children's Hospital for malnutrition, chronic diarrhea, dehydration, and growth retardation. His weight (3080 g), height (57 cm), and head circumference (36 cm) were below the third percentile. Physical examination revealed skin turgor and subcutaneous fat loss. He had acanthocytes in the blood smear (not shown). Plasma levels of aspartate aminotransferases were elevated, but alanine aminotransferases were normal (Table) . Although plasma vitamin E levels were low, neurological examination was negative. Hepatic ultrasound showed fatty liver. Parents refused consent for hepatic or intestinal biopsy. Viral hepatitis markers were negative. At the hospital, the patient received fresh frozen plasma and vitamin K to combat prolonged coagulation tests (prothrombin time: 130 s, normal <16 s; international normalized ratio: >10, normal, <1.2). Plasma high-density lipoprotein cholesterol and apoA1 levels were near the normal range. Plasma total cholesterol levels were 23% to 41% of male children (Table) . Plasma triglyceride, low-density lipoprotein cholesterol, and apoB were not detectable. The mother had normal plasma lipids (Table) . The proband was started on a high-calorie (150 kcal/kg), low-fat (<30%) diet containing medium-chain triglycerides and fatsoluble vitamins (vitamin A, 5000 U per day; vitamin D, 1000 U per day; vitamin E, 100 U/kg per d; and vitamin K, 5 mg per week). He gained 910 g in 2 months. At 3 years, his neurological and motor development was compatible with his age. The child was from a consanguineous marriage between first cousins ( Figure II in the Data Supplement ). The proband's brother also presented with growth retardation and died of unknown causes at 18 months. The proband's sisters were healthy.
Mutation in the MTTP Gene
Clinical manifestations suggested the diagnosis of abetalipoproteinemia. Sequencing of the MTTP gene revealed that the proband was homozygous and the mother was heterozygous for a novel A>T transition in the exon 5 (Ex. 5 c.506 A>T) resulting in a change of amino acid 169 from aspartic acid to valine (D169V). Other family members were not available for testing.
D169V Does Not Support ApoB48 Secretion
To determine whether D169V was responsible for the abetalipoproteinemia phenotype, we generated the mutation in a C-terminally FLAG-tagged human MTTP plasmid 37,42 via site-directed mutagenesis. Cos-7 cells, which do not express apoB and MTP, were sequentially transfected with plasmids expressing human apoB48 (pCMV-hApoB48) 38 and plasmids expressing MTP or D169V. Despite similar intracellular levels of apoB48 ( Figure 1A ), cells expressing D169V had significantly lower amounts of secreted apoB48 compared with cells expressing MTP ( Figure 1B) . Cellular MTP and D169V protein levels were similar ( Figure 1C ). Therefore, D169V was expressed normally, but it was unable to support apoB48 secretion. The inability of D169V to support apoB48 secretion probably contributes to the abetalipoproteinemia phenotype in the proband.
The N-terminal region has not been implicated in lipid transfer activity. 25, 30, 33 Therefore, we investigated why D169V does not support apoB secretion by evaluating its effect on intracellular localization, apoB binding, triglyceride transfer, phospholipid transfer, and PDI binding.
D169V Localizes to ER and Binds ApoB17
MTP must be expressed in the ER, the site of the assembly of apoB-containing lipoproteins. Immunofluorescent staining showed that both MTP and D169V colocalized with calnexin, an ER marker ( Figure 1D ), and therefore, they are present in the ER.
Because the N-terminal region of MTP binds the N-terminal 17% of apoB, 1, 6, 43 we hypothesized that D169V may interfere with apoB17 binding. To evaluate protein-protein interactions, cells were cotransfected with plasmids expressing apoB17 and plasmids expressing WT or D169V. First, we immunoprecipitated apoB17 and determined the amounts of apoB17 and MTP present in the immunoprecipitates by Western blotting. Anti-apoB antibodies pulled down similar amounts of apoB17. These precipitates contained similar amounts of MTP and D169V ( Figure 1E ). No MTP was precipitated in cells transfected with MTP and no apoB. Second, we observed similar amounts of apoB and MTP in the precipitates obtained with anti-FLAG antibody ( Figure 1F ). Therefore, D169V does not affect the ability of MTP to bind apoB17.
D169V Does Not Transfer Lipids
Previously characterized abetalipoproteinemia mutants lack phospholipid and triglyceride transfer activities. 30 MTP efficiently transferred phospholipids between vesicles, whereas D169V showed decreased (−91%) phospholipid transfer activity ( Figure 2A ). As expected, cells expressing MTP showed robust triglyceride transfer activity, whereas D169V cells showed low triglyceride transfer activity (−87%; Figure 2B ). Thus, D169 is important for the phospholipid and triglyceride transfer activities of MTP.
D169V Does Not Bind PDI
Because heterodimerization between the M subunit and PDI is required for lipid transfer activities of MTP, 22 we determined whether D169V could bind PDI. Immunofluorescent staining for FLAG and PDI illustrated that both WT and D169V colocalize with PDI ( Figure 2C ). To determine whether MTP and PDI physically interact, MTP proteins were immunoprecipitated with anti-FLAG antibodies and Western blotted for FLAG and PDI. Comparable amounts of MTP-FLAG proteins were immunoprecipitated indicating similar expression ( Figure 2D ). Significant amounts of PDI were immunoprecipitated with MTP but not with D169V. Thus, despite being in the same subcellular compartment, PDI and D169V do not seem to interact. Furthermore, D169V showed decreased solubility (−45%) compared with WT ( Figure 2E ).
Identification of a Possible D169-K187-K189 Salt Bridge
PDI interacts with the α-helical region of MTP, whereas the lipid binding and transfer domain are in the C-terminus. 6, 23 To understand why D169V, located in the N-terminus, affects PDI binding and lipid transfer, we visualized the location of D169 in an MTP model built on homology with lipovitellin. D169 is located at the C-terminus of the seventh β-strand ( Figure  3A and 3B) . Surface disposition analysis revealed that D169 is buried in the center of the β-barrel ( Figure 3C ). Therefore, we hypothesized that the negatively charged aspartic acid might form salt bridges or hydrogen bonds with positively charged amino acids. Two positive residues, K187 and K189, are within 4 Å of the carboxyl group of D169, suggesting that these 2 residues may form a salt bridge ( Figure 3D ).
K187L and K189L Abolish PDI Binding, Lipid Transfer, and ApoB48 Secretion
To evaluate the possibility of an internal salt bridge needed for MTP activity, we mutated K187 and K189 to leucines that have the same number of side-chain carbon atoms but lack positive charges (Figure II in the Data Supplement). Cells expressing K187L and K189L had intracellular apoB48 levels similar to those in WT MTP expressing cells ( Figure 4A ), but the amounts of apoB48 in the media of cells expressing K187L and K189L were significantly lower ( Figure 4B ).
Several possibilities for the inability of K187L and K189L to support apoB secretion were evaluated. These mutants were in the ER ( Figure 4C with apoB17 ( Figure 4E and 4F) , and colocalized with PDI ( Figure 5A ). However, their ability to heterodimerize with PDI was markedly reduced ( Figure 5B ), and they were only partially (25%-41%) soluble compared with MTP ( Figure 5C ). Mutagenesis of these residues also reduced triglyceride (−84% and −68%; Figure 5D ) and abolished phospholipid (92%-100%; Figure 5E ) transfer activities. Therefore, like D169, K187 and K189 are required for PDI binding, lipid transfer, and apoB secretion.
D169E, K187R, and K189R Restore PDI Binding, Lipid Transfer, and ApoB Secretion
To test whether the charges at 169, 187, and 189 are important for MTP activity, aspartic acid and lysines were replaced with glutamic acid (D169E) or arginines (K187R and K189R). All mutants colocalized with calnexin ( Figure 6A ), expressed similarly as WT ( Figure 6B ), interacted with apoB17 ( Figure 6C and 6D) , colocalized with PDI ( Figure 7A ), and heterodimerized with PDI ( Figure 7B ). D169E was partially soluble (≈61% of WT), whereas K187R had similar solubility to WT ( Figure 7C ). K189R was completely soluble ( Figure 7C ). Hence, reinstating charges at 169, 187, and 189 restore PDI binding and solubility of the M subunit.
We then asked whether the restoration of charges at these residues is sufficient to regain lipid transfer function. D169E partially rescued triglyceride ( Figure 7D ) and phospholipid transfer ( Figure 7E ; −36% and −41% compared with WT, respectively). K187R and K189R were also able to partially transfer triglyceride (79% and 55% of WT; Figure 7D ). K187R and K189R, however, were able to transfer phospholipid similar to WT ( Figure 7E ). Thus, glutamic acid at 169 partially restores triglyceride and phospholipid transfer, whereas arginine residues at 187 and 189 partially restore triglyceride transfer but completely restore phospholipid transfer.
Finally, we determined whether preservation of charges would support apoB48 secretion. Intracellular apoB levels were similar in cells transfected with apoB48 and mutant MTPs ( Figure 7F ). D169E was ≈50% as efficient as the WT in supporting apoB48 secretion ( Figure 7G) . Surprisingly, K187R and K189R were able to support apoB48 secretion similar to WT ( Figure 7G ). Thus, these charged residues are indispensable for lipid transfer and apoB48 secretion.
Discussion
We report an abetalipoproteinemia patient with a novel, homozygous, missense mutation, D169V, in the N-terminal region of MTP. This rare mutation is not reported in various populations in Exome Variation Sequence, SNP, 1000 genomes, or various HAPMAP databases. 44 Although D169V interacts with apoB, it is unable to support apoB secretion, transfer lipids, or bind PDI, suggesting that this mutation may cause abetalipoproteinemia.
Previously reported missense mutations in the N-terminal region are polymorphisms found in multiple populations. They are solvent exposed and do not seem to interact with any other side chains ( Figure IIIA in the Data Supplement). Furthermore, they are predicted to be benign by SIFT, Polyphen, and Panther. Computational mutagenesis of these residues does not affect the structure of β-barrel, suggesting that this region may not be as critical for the function of MTP as the middle α-helical and C-terminal domains. In contrast to these predictions, we provided the first evidence for the importance of the N-terminal domain in MTP function and found that the D169V mutation damages the function of MTP.
Salt-Bridge Identification
Because the N-terminal β-barrel had not been implicated in PDI binding and lipid transfer activities, it was initially unclear why and how D169 could be detrimental. Evidence for the importance of D169, K187, and K189 residues as part of an essential internal salt bridge came from mutagenesis studies that abolished or replaced charges at these positions. Eliminating the charges abolished PDI binding, lipid transfer activities, and apoB48 secretion with no detrimental effect on apoB17 binding. Restoration of charges at these positions rescued MTP activity to different extents. D169E partially restored PDI binding, lipid transfer, and apoB48 secretion, indicating that aspartic acid at 169 is optimal and glutamic acid at this site is suboptimal. In contrast, K187R and K189R were able to completely rescue PDI binding, apoB48 secretion, and phospholipid transfer similar to WT, indicating that arginines at these positions can form optimal salt bridges with D169 similar to lysines. Electrostatic interactions help stabilize the secondary and tertiary structures of proteins. When D169 was mutated to D169V in UCSF Chimera and analyzed for detecting clashes among side chains using the cutoff values of 0.4 to 1.0 Å and allowance values of 0.2 to 0.6 Å, D169V destabilized K189, whereas D169E did not. Therefore, D169V might perturb the secondary and tertiary structures. However, these perturbations do not affect apoB17 binding, suggesting that the N-terminal domain may have 2 independent microdomains.
Further modeling studies suggest that the D169-K187-K189 salt bridge might include E167 (seventh β-strand), S171 (eighth β-strand), and Y178 (eighth β-strand; Figure 8B) , as K187 and K189 may interact with E167 and S171, respectively ( Figure 8B ). Furthermore, E167 is within hydrogen-bonding distance of Y178 ( Figure 8B) . Therefore, there probably exists an extended salt bridge in this region that may provide structural stability for the seventh to ninth β-strands and form a microdomain in the N-terminal β-barrel. Evidence for the importance of these residues involved in a possible extended salt bridge can be garnered from bioinformatics. These residues are highly conserved ( Figure 8A) , and their mutagenesis is predicted to be detrimental to the function of MTP by Polyphen, 45 Panther, 46 and SIFT 47 algorithms. Other polymorphisms in these β-strands do not affect the predicted tertiary structure ( Figure IIIB in the Data Supplement). Furthermore, no mutagenesis studies involving these residues have been reported. Therefore, we predict that E167, S171, or Y178 residues may be part of an extended salt bridge, and mutations at these residues may affect MTP activity and cause abetalipoproteinemia. We speculate that this microdomain might be further stabilized by a disulfide bond between C174 (eighth β-strand) and C194 (ninth β-strand; Figure 8B ). Disruption of the disulfide bond decreases solubility and triglyceride transfer activity of MTP, 23 but it is unknown whether this disruption interferes with PDI binding. Thus, these studies point to the likely presence of an essential microdomain, including β-strands 7 to 9, that is stabilized by an internal salt bridge and possibly by a disulfide bond.
Role of the Salt Bridge in Phospholipid and Triglyceride Transfer Activities
Mutagenesis studies and missense mutations have implicated the middle α-helical and C-terminal domains of MTP in lipid transfer activities. 23, 24, 27, 28, 30, 31 This study suggests that the N-terminal domain is also important for lipid transfer activity. The absence of triglyceride and phospholipid transfer activities in D169V, K187L, and K189L is not secondary to the aggregation or the absence of these proteins during assay conditions; they were only partially insoluble, but they were almost completely deficient in triglyceride transfer activity. Likely, these decreases were a direct consequence of the mutations.
Role of the D169 in PDI Binding
Missense mutations that abolish PDI binding have been identified in helices 13 to 17 of the middle α-helical domain ( Figure 8C, yellow) . Furthermore, a truncated MTP mutant missing the last 20 amino acids does not bind PDI. 27 Here, we identified a microdomain in the N-terminal region located on the same plane as helices 13 to 17 in the middle α-helical region that is critical for PDI binding (Video I in the Data Supplement). Therefore, we propose that PDI interacts with all the 3 domains of the M subunit and acts as a framework to stabilize structural domains essential for lipid transfer activity.
ApoB-Binding Domain Might Be Upstream of the Microdomain Containing D169
Because the N-terminal region of MTP was shown to bind apoB, 23, 26, 48 we had theorized that D169V may interfere with apoB-MTP interactions. Surprisingly, mutating D169 or other residues of the salt bridge did not affect its ability to bind apoB17. Therefore, we hypothesize that the N-terminal domain may contain 2 microdomains. These studies show that 1 microdomain, involving β-strands 7 to 9, is involved in PDI binding. β-strands 1 to 3 and α-helix NH1, upstream of D169, may form an independent microdomain that might interact with apoB ( Figure 8D ; Video I in the Data Supplement). Mutagenesis of charged residues in the β-strands 1 to 
Implications for Targeting MTP
MTP inhibitors are not approved for more common use because they cause hepatosteatosis, increase plasma transaminases, and exhibit gastrointestinal side effects. In silico identification of more efficacious MTP inhibitors is hindered because MTP has not been crystallized. The functional characterization of D169, K187, and K189, as well as bioinformatic modeling of the N-terminal domain, contributes to the structural and functional map of MTP. The data presented here suggest that molecules that interact with β-strands 7 to 9 in the N-terminus may disrupt PDI binding and inhibit lipid transfer activities, resulting in steatosis similar to existing inhibitors that also target lipid transfer activity. Therefore, we advocate avoidance of this microdomain for targeting. Instead, we speculate that targeting β-strands 1 to 3 and helix NH1 may reduce apoB-MTP binding without affecting lipid transfer activity. Small molecule inhibitors or mutations in apoB that target the chaperone activity of MTP without affecting the lipid transfer activity of MTP reduce apoB secretion, but in vivo data for intracellular lipid accumulation is lacking. 29, 49 As these inhibitors would not affect lipid transfer activity, MTP may still assist in the formation of lumenal lipid droplets that can fuse with nascent apoB-containing lipoproteins, be secreted, and reduce steatosis. Alternatively, similar to antisense oligonucleotide to apoB100 and lipid transfer inhibitors of MTP, 12 inhibition of the chaperone activities of MTP may also cause steatosis. Identification of missense mutations that affect only the chaperone activity of MTP and in vivo studies of the MTP inhibitor that affects apoB binding are warranted.
In summary, this study presents a patient with abetalipoproteinemia carrying a novel mutation, D169V, in the N-terminal region of MTP. Our studies show that (1) D169V does not affect protein expression, localization to the ER, or apoB17 binding; (2) it reduces PDI binding, solubility, lipid transfer activities, and apoB48 secretion; and (3) D169 is probably involved in an internal salt bridge that is important for these functions. These studies also show that apoB binding may be discrete from lipid transfer and PDI binding. We propose that the N-terminal region of MTP is divided into 2 independent microdomains. It might be possible to target apoB binding and to assess whether such inhibitors might be better than pan inhibitors in the treatment of hyperlipidemias. Figure 8 . Evolutionary conservation and hypothetical models show extended E167-D169-S171-Y178-K187-K189 salt bridge and protein disulfide isomerase (PDI) binding site. A, Amino acids 163 to 195 in β-strands 7 to 9 of microsomal triglyceride transfer protein orthologs were aligned using Clustal Omega. Arrowheads point to the members of the extended salt bridge (E167, D169, S171, Y178, K187, and K189). Green arrows below represent the secondary structure of this region. B, Magnified interior of the N-terminal β-barrel. Amino acid side chains that could possibly interact with other members of the extended salt bridge are shown. The blue lines represent possible electrostatic interactions. C, The 2 major binding sites for PDI are in yellow. This study identified the importance of the N-terminal β-strands 7 to 9 in PDI binding. Middle α-helices 13 to 17 have been previously shown to interact with PDI. D, Expanded view of the N-terminal domain illustrating the 2 microdomains. β-strands 7 to 9 (yellow) are necessary for PDI binding. β-strands 1 to 3 (orange) and helix NH1 (red) may be involved in apoB binding. Helix NH2 (purple) appears to divide these 2 microdomains.
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